We are live on ! Find out more
LCTX icon

Lineage Cell Therapeutics
LCTX

107 hedge funds and large institutions have $113M invested in Lineage Cell Therapeutics in 2018 Q2 according to their latest regulatory filings, with 9 funds opening new positions, 33 increasing their positions, 21 reducing their positions, and 17 closing their positions.

New
Increased
Maintained
Reduced
Closed

57% more repeat investments, than reductions

Existing positions increased: 33 | Existing positions reduced: 21

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

1.31% less ownership

Funds ownership: 50.87% → 49.55% (-1.3%)

7% less funds holding

Funds holding: 115 → 107 (-8)

25% less capital invested

Capital invested by funds: $152M → $113M (-$38.5M)

34% less call options, than puts

Call options by funds: $109K | Put options by funds: $164K

47% less first-time investments, than exits

New positions opened: 9 | Existing positions closed: 17

Holders
107
Holders Change
-8
Holders Change %
-6.96%
% of All Funds
2.45%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.05%
New
9
Increased
33
Reduced
21
Closed
17
Calls
$109K
Puts
$164K
Net Calls
-$55K
Net Calls Change
-$265K

Top Buyers

1
BlackRock
BlackRock
New York
+$1.33M
2
Vanguard Group
Vanguard Group
Pennsylvania
+$556K
3
State Street
State Street
Massachusetts
+$417K
4
Two Sigma Investments
Two Sigma Investments
New York
+$147K
5
Geode Capital Management
Geode Capital Management
Massachusetts
+$124K

Top Sellers

1
Renaissance Technologies
Renaissance Technologies
New York
-$1.45M
2
DWM
Destination Wealth Management
California
-$1.42M
3
Deutsche Bank
Deutsche Bank
Germany
-$1M
4
MHP
Manatuck Hill Partners
Connecticut
-$747K
5
LCM
Laurion Capital Management
New York
-$472K
Name Holding Trade Value Shares
Change 		Change in
Stake
Citadel Advisors
26
Citadel Advisors
Florida
$173K -$213K -105,587 -52%
Commonwealth Equity Services
27
Commonwealth Equity Services
Massachusetts
$169K +$2.3K +1,143 +1%
WJA
28
Williams Jones & Associates
New York
$166K – – –
Manulife (Manufacturers Life Insurance)
29
Manulife (Manufacturers Life Insurance)
Ontario, Canada
$164K +$17.3K +8,587 +10%
New York State Common Retirement Fund
30
New York State Common Retirement Fund
New York
$143K – – –
RJFSA
31
Raymond James Financial Services Advisors
Florida
$132K -$11.5K -5,715 -7%
Goldman Sachs
32
Goldman Sachs
New York
$130K +$56.6K +28,094 +63%
AIG
33
American International Group
New York
$120K +$6.84K +3,397 +5%
State of Wisconsin Investment Board
34
State of Wisconsin Investment Board
Wisconsin
$117K – – –
Wells Fargo
35
Wells Fargo
California
$106K -$206K -102,404 -63%
California Public Employees Retirement System
36
California Public Employees Retirement System
California
$100K – – –
MC
37
Moors & Cabot
Massachusetts
$94K -$14.7K -7,292 -12%
RA
38
Raffles Associates
New York
$93K +$104K +51,435 New
SFA
39
Sequoia Financial Advisors
Ohio
$88K -$14K -6,953 -12%
Bank of America
40
Bank of America
North Carolina
$87K -$30.9K -15,332 -24%
Invesco
41
Invesco
Georgia
$80K -$156K -77,279 -63%
CA
42
Corrado Advisors
New Jersey
$80K – – –
GPCM
43
Granite Point Capital Management
Massachusetts
$78K -$198K -98,594 -70%
Ameriprise
44
Ameriprise
Minnesota
$78K -$62.3K -30,939 -42%
PPA
45
Parametric Portfolio Associates
Washington
$77K +$3.02K +1,499 +4%
UBS AM
46
UBS AM
Illinois
$74.6K – – –
IP
47
Intellectus Partners
California
$73K – – –
VOYA Investment Management
48
VOYA Investment Management
Georgia
$67K – – –
SC
49
Scotia Capital
Ontario, Canada
$66K – – –
Russell Investments Group
50
Russell Investments Group
United Kingdom
$65K +$5.06K +2,514 +8%
1
2
3 4 5

LCTX Hedge Fund Activity: Q2 2018 in Review

107 of the 4,368 institutional investors tracked by Wall St. Rank reported a position in Lineage Cell Therapeutics (LCTX) for Q2 2018, worth a combined $113M — down 25% from $152M a quarter earlier.

Sellers outnumbered buyers: 17 funds closed out of LCTX and 9 opened new positions — a net loss of 8 holders — while 21 trimmed existing stakes and 33 added.

The largest buyer was BlackRock, adding an estimated $1.33M. The largest seller was Renaissance Technologies, cutting an estimated $1.45M.

  • 107 institutional investors held Lineage Cell Therapeutics (LCTX) as of Q2 2018, down from 115 in Q1 2018.
  • Funds reported $113M of Lineage Cell Therapeutics stock for Q2 2018, down 25% quarter-over-quarter.
  • 9 funds opened new Lineage Cell Therapeutics positions in Q2 2018 and 17 closed out, a net change of -8 holders.
  • The largest Lineage Cell Therapeutics buyer in Q2 2018 was BlackRock, an estimated $1.33M added.
  • The largest Lineage Cell Therapeutics seller in Q2 2018 was Renaissance Technologies, an estimated $1.45M sold.

Based on aggregated 13F filings for Q2 2018.